This study looks at the health of **corneal endothelial cells** (special eye cells) in people with a condition called **neovascular age-related macular degeneration (nAMD)**. nAMD is an eye disease that can cause vision loss. Participants will be treated with a **Port Delivery System (PDS)** that delivers a medicine called **Ranibizumab** to the eye. The PDS needs refilling every 24 weeks. To join, participants must have had nAMD diagnosed within the last 18 months and meet specific eye health criteria. Key exclusions include any recent eye surgery, eye infections, or other serious eye conditions. Participants with certain systemic health issues, like uncontrolled blood pressure or recent heart conditions, may also be excluded. **Key Points for Participation:** - **Length of Study:** Long-term participation is required as PDS is refilled every 24 weeks. - **Compensation and Visits:** Details on compensation and number of required visits are not specified. - **Risks and Considerations:** Participants should consider potential risks like complications from the PDS and ensure they meet the strict health requirements. Note: Always consult with your healthcare provider before joining any clinical study.